Alentis Therapeutics Funding: $366M Raised, Series D (2024)
Alentis Therapeutics is based in Basel, Switzerland. It has raised $366M in total funding. Latest round: Series D.
Alentis Therapeutics funding overview
Alentis Therapeutics is based in Basel, Switzerland. Alentis Therapeutics has raised $366M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in November 2024. The round record for Alentis Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include OrbiMed, Novo Holdings, Jeito Capital, Frazier Life Sciences, Longitude Capital, Catalio Capital and 6 others. 12 distinct backers are named across the disclosed rounds.
Alentis Therapeutics at a glance
Total raised
$366M
Latest round
Series D
Latest round date
November 2024
Headquarters
Basel, Switzerland
Notable investors
OrbiMed, Novo Holdings, Jeito Capital, Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, Avego Bioscience Capital
Frequently asked about Alentis Therapeutics funding
How much has Alentis Therapeutics raised?
Alentis Therapeutics has raised $366M in total disclosed funding across the rounds on record.
Who has invested in Alentis Therapeutics?
OrbiMed, Novo Holdings, Jeito Capital, Frazier Life Sciences, Longitude Capital, Catalio Capital are named among the investors backing Alentis Therapeutics.
What was the latest Alentis Therapeutics funding round?
The most recent disclosed round is a Series D, announced in November 2024.
Where is Alentis Therapeutics based?
Alentis Therapeutics is based in Basel, Switzerland.
When did Alentis Therapeutics last raise?
The last disclosed Alentis Therapeutics round closed in November 2024 at Series D.
Every Alentis Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Basel at a similar stage.
